Skip to main content

Table 7 Table of adverse events

From: The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data

  Neutropenia a, b between day 1 and day 28 Anemia a, b between day 1 and day 28 Diarrhea between day 1 and day 7 Vomiting c between day 1 and day 7 Acute drug vomiting
AQ dose category (mg/kg) d      
<25 7.0% (5/71) 19.3% (79/410) 4.7% (11/232) 9.3% (24/258) 4.7% (10/214)
25 to <30 20.4% (33/162) 24.1% (190/787) 6.5% (56/857) 9.7% (81/838) 12.9% (80/622)
30 to <35 17.9% (21/117) 21.3% (132/621) 5.8% (55/955) 9.9% (92/933) 11.3% (55/486)
35 to <40 35.3% (30/85) 24.8% (96/387) 7.1% (49/693) 11.3% (74/656) 12.5% (54/433)
40 to <45 30.8% (8/26) 26.9% (58/216) 7.4% (43/580) 13.9% (76/546) 14.7% (62/423)
≥45 21.4% (6/28) 25.7% (35/136) 15.1% (76/504) 12.9% (63/490) 19.1% (33/173)
Age category      
<1 y 30.0% (15/50) 49.6% (64/129) 18.4% (52/282) 6.6% (19/287) 21.4% (27/126)
1 to <5 y 17.3% (44/255) 28.0% (437/1,558) 7.4% (189/2,565) 8.7% (228/2,611) 13.9% (230/1,655)
5 to <12 y 13.3% (14/105) 12.4% (50/402) 3.2% (16/505) 15.8% (69/436) 8.9% (26/292)
≥12 y 38.0% (30/79) 8.3% (39/468) 7.0% (33/469) 24.3% (94/387) 4.0% (11/278)
Overall 21.1% (103/489) 23.1% (590/2,557) 7.6% (290/3,821) 11.0% (410/3,721) 12.5% (294/2,351)
  1. aPresented only for patients without neutropenia/anemia at baseline.
  2. bNeutropenia defined as ≤1,200 neutrophils/μl for <12 years and ≤1,500 neutrophils/μl for ≥12 years. Anemia defined as hemoglobin < 10 g/dl.
  3. cExcludes acute drug vomiting within an hour of treatment administration.
  4. dAfter adjusting for age category and formulation, AOR = 1.17 [95% CI: 0.95-1.46]; P = 0.144 for the risk of neutropenia for every 5 mg/kg increase in AQ dose.
  5. dAfter adjusting for age category and formulation, AOR = 1.16 [95% CI: 1.07-1.24]; P < 0.001 for the risk of diarrhea for every 5 mg/kg increase in AQ dose.
  6. dAfter adjusting for age category and formulation, AOR = 1.20 [95% CI: 1.11-1.29]; P < 0.001 for the risk of general vomiting for every 5 mg/kg increase in AQ dose.
  7. dAfter adjusting for age category and formulation, AOR = 1.23 [95% CI: 1.11-1.36]; P < 0.001 for the risk of acute vomiting for every 5 mg/kg increase in AQ dose.